AstraZeneca (AZN) said its Saphnelo or anifrolumab has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patients with systemic lupus erythematosus on top of standard therapy. The CHMP based its positive opinion on interim results from the Phase III TULIP-SC trial.
AstraZeneca acquired global rights to?Saphnelo?through an exclusive license and collaboration agreement with Medarex in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. AstraZeneca will pay BMS a low to mid-teens royalty for sales dependent on geography.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.